

Geert-Jan Creemers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6873130/publications.pdf>

Version: 2024-02-01

63
papers

1,696
citations

430874

18
h-index

315739

38
g-index

63
all docs

63
docs citations

63
times ranked

1987
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Intestinal Microbiota in Metastatic Colorectal Cancer Patients Treated With Capecitabine. <i>Clinical Colorectal Cancer</i> , 2022, 21, e87-e97.	2.3	6
2	UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. <i>European Journal of Cancer</i> , 2022, 162, 148-157.	2.8	27
3	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1220-1230.	1.6	274
4	Beyond median overall survival: Estimating multiple survival scenarios in patients with metastatic esophagogastric cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 261-261.	1.6	1
5	MRI tumour regression grade in locally recurrent rectal cancer. <i>BJS Open</i> , 2022, 6, .	1.7	7
6	Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). <i>Clinical Colorectal Cancer</i> , 2022, 21, 154-166.	2.3	6
7	Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. <i>Frontiers in Oncology</i> , 2022, 12, 839779.	2.8	9
8	Quality of life and quality of care as experienced by patients with advanced cancer and their relatives: A multicentre observational cohort study (eQuiPe). <i>European Journal of Cancer</i> , 2022, 165, 125-135.	2.8	22
9	Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. <i>European Journal of Cancer</i> , 2022, 172, 231-233.	2.8	0
10	Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era. <i>British Journal of Cancer</i> , 2021, 124, 399-406.	6.4	19
11	Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. <i>European Journal of Surgical Oncology</i> , 2021, 47, 699-707.	1.0	18
12	A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. <i>Cancers</i> , 2021, 13, 839.	3.7	2
13	Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancer. <i>Journal of Cancer Survivorship</i> , 2021, 15, 380-385.	2.9	4
14	Implementation of a regional video multidisciplinary team meeting is associated with an improved prognosis for patients with oesophageal cancer A mixed methods approach. <i>European Journal of Surgical Oncology</i> , 2021, 47, 3088-3096.	1.0	9
15	Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases—a systematic review. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S242-S258.	1.4	13
16	Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3574-3574.	1.6	3
17	TGF- β 2 and PD-L1 inhibition combined with definitive chemoradiotherapy in esophageal squamous cell carcinoma: A phase II clinical trial (NCT04595149).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4154-TPS4154.	1.6	1
18	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1995-2004.	1.6	291

#	ARTICLE	IF	CITATIONS
19	Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency. <i>Clinical Colorectal Cancer</i> , 2021, 20, 359-363.	2.3	2
20	The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer. <i>European Journal of Cancer</i> , 2021, 156, 60-69.	2.8	2
21	Experienced quality of care and emotional functioning of patients with advanced cancer and their relatives: Results of a multicenter observational cohort study (eQuiPe).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3-3.	1.6	6
22	First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-8.	4.9	6
23	Metabolic PET/CT response after induction chemotherapy and chemo(re)irradiation is associated with higher negative resection margins rate in patients with locally recurrent rectal cancer. <i>Colorectal Disease</i> , 2021, , .	1.4	3
24	Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study. <i>International Journal of Cancer</i> , 2020, 146, 1889-1901.	5.1	29
25	The prognostic relevance of histologic subtype in appendiceal adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2020, 46, 433-438.	1.0	2
26	The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. <i>Hpb</i> , 2020, 22, 233-240.	0.3	66
27	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 462-471.	1.6	44
28	Prospective cohort study of patients with advanced cancer and their relatives on the experienced quality of care and life (eQuiPe study): a study protocol. <i>BMC Palliative Care</i> , 2020, 19, 139.	1.8	21
29	Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study. <i>European Journal of Cancer</i> , 2020, 139, 107-118.	2.8	10
30	Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. <i>Acta Oncologica</i> , 2020, 59, 705-712.	1.8	9
31	Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. <i>Gastric Cancer</i> , 2020, 23, 579-590.	5.3	16
32	Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 704-711.	4.9	14
33	Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1354-1363.	4.9	11
34	Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study. <i>Targeted Oncology</i> , 2019, 14, 699-705.	3.6	7
35	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. <i>Cancers</i> , 2019, 11, 1212.	3.7	21
36	Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 803-813.	7.3	65

#	ARTICLE	IF	CITATIONS
37	Palliative chemotherapy for patients with synchronous metastases of smallâ€bowel adenocarcinoma: A reflection of daily practice. <i>United European Gastroenterology Journal</i> , 2019, 7, 1380-1388.	3.8	2
38	A cost analysis of upfront DPYD genotypeâ€guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019, 107, 60-67.	2.8	65
39	Review: Pathology and Its Clinical Relevance of Mucinous Appendiceal Neoplasms and Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , 2019, 18, 1-7.	2.3	25
40	QoL from TASCO1: Health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapyâ€Results from the TASCO1 phase II study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 676-676.	1.6	2
41	Salvage endoscopic resection in patients with esophageal adenocarcinoma after chemoradiotherapy. <i>Endoscopy International Open</i> , 2018, 06, E1126-E1129.	1.8	4
42	Capecitabine-Associated Terminal Ileitis. <i>Case Reports in Oncology</i> , 2018, 11, 654-659.	0.7	13
43	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology</i> , The, 2018, 19, 1459-1467.	10.7	238
44	Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4057-4057.	1.6	4
45	Pharmacogenetic analysis of irreversible severe cisplatinâ€induced nephropathy: a case report of a 27â€yearâ€old woman. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2120-2122.	2.4	5
46	The impact of age on first-line systemic therapy in patients with metachronous metastases from colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2017, 8, 37-43.	1.0	6
47	Impact of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) on time to progression and overall survival (OS) in metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10087-10087.	1.6	4
48	Bevacizumab in Addition to Palliative Chemotherapy for Patients With Peritoneal Carcinomatosis of Colorectal Origin: A Nationwide Population-Based Study. <i>Clinical Colorectal Cancer</i> , 2016, 15, e41-e46.	2.3	32
49	Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: Results of a population-based study. <i>European Journal of Cancer</i> , 2016, 65, 113-120.	2.8	45
50	Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer. <i>Acta Oncol</i> ³gica, 2016, 55, 1443-1449.	1.8	6
51	The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide populationâ€based analysis. <i>Cancer Medicine</i> , 2016, 5, 2825-2831.	2.8	57
52	Prospectively measured lifestyle factors and BMI explain differences in health-related quality of life between colorectal cancer patients with and without comorbid diabetes. <i>Supportive Care in Cancer</i> , 2016, 24, 2591-2601.	2.2	13
53	Developing a core set of patient-reported outcomes in pancreatic cancer: A Delphi survey. <i>European Journal of Cancer</i> , 2016, 57, 68-77.	2.8	33
54	Local Recurrence in the Lateral Lymph Node Compartment: Improved Outcomes with Induction Chemotherapy Combined with Multimodality Treatment. <i>Annals of Surgical Oncology</i> , 2016, 23, 1883-1889.	1.5	12

#	ARTICLE	IF	CITATIONS
55	Does long-term survival exist in pancreatic adenocarcinoma?. <i>Acta Oncol</i> 2016, 55, 259-264.	1.8	22
56	Predictive value of KRAS mutation status in metastatic colorectal cancer (mCRC) patients treated with capecitabine and bevacizumab (CAP-B) maintenance treatment vs observation in the phase III CAIRO3 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3525-3525.	1.6	3
57	Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3640-3640.	1.6	1
58	Deciding on adjuvant chemotherapy for elderly patients with stage III colon cancer: A qualitative insight into the perspectives of surgeons and medical oncologists. <i>Journal of Geriatric Oncology</i> , 2015, 6, 219-224.	1.0	7
59	The Prognostic Relevance of Histological Subtype in Patients With Peritoneal Metastases From Colorectal Cancer: A Nationwide Population-Based Study. <i>Clinical Colorectal Cancer</i> , 2015, 14, e13-e19.	2.3	20
60	Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).. <i>Journal of Clinical Oncology</i> , 2013, 31, 3502-3502.	1.6	29
61	Distant recurrences of colorectal cancer: Incidence, systemic treatment, and survival in daily practice.. <i>Journal of Clinical Oncology</i> , 2013, 31, 441-441.	1.6	1
62	CEA response as a predictive marker for response according to RECIST in patients with KRAS wild-type metastatic colorectal cancer (KRAS WT mCRC) (pts) treated with panitumumab monotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 574-574.	1.6	1
63	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases in patients with colorectal cancer. <i>The Cochrane Library</i> , 0, , .	2.8	0